Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b study of S-337395 in high-risk nonhospitalized adults with RSV
2025-523156-31-00Phase 2Authorised
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial in respiratory syncytial virus disease (RSV) comparing S-337395 with Placebo (2 arms). Primary endpoint: Change from baseline in RSV RNA load. Planned start Nov 2025; status: authorised.
02
Drugs
S-337395
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on 2025-523156-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523156-31-00.